Free Health Information and More for You and Your Family, Updated Weekly
Mannkind Corp. Bets on Inhaled Insulin
LOS ANGELES,
Nov. 17 (UPI) -- Mannkind Corp. is betting that its inhalable insulin will
be a hit with diabetes patients despite Pfizer's decision to stop selling
a similar product.
Mannkind Chief
Executive Alfred E. Mann said his inhalable insulin is medically superior
to the product Pfizer pulled of the market last month because of poor sales,
The Los Angeles Times reported Friday. The newspaper said Mann is putting
nearly $1 billion of his own money on the effort.
"I believe this
is one of the most valuable products in history in the drug industry, and
I'm willing to back it up with my estate," Mann said.
MannKind, which
is based in Valencia, Calif., is in the final stage of clinical trials
for Technosphere Insulin. Mann said the company would be ready by the end
of next year to apply for federal approval to sell the drug for Type 1
and Type 2 diabetes.
